Results for trombocyttransfusion translation from Danish to English

beslutningen om at foretage trombocyttransfusion bør baseres på en individuel klinisk vurdering.
the decision to use platelet transfusions should be based upon clinical judgment on an individual basis.

infusion af pbpc accelererer hæmatopoietisk bedring med reduktion af varigheden for risiko for hæmoragiske komplikationer og behov for trombocyttransfusion.
infusion of pbpcs accelerates haematopoietic recovery reducing the duration of risk for haemorrhagic complications and the need for platelet transfusions.

trombocytter < 50 x 109/l trombocytopeni kompliceret af blødning eller som kræver blod- eller trombocyttransfusion
platelets < 50 x 109/l thrombocytopenia complicated by haemorrhage or requiring blood or platelet transfusion

trombocytopeni (< 25x109/l eller behov for trombocyttransfusion) forekom hos 100 % af de pædiatriske patienter.
in children, thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred in 100% of patients.

trombocyttransfusion reverterede ikke den trombocytfunktionshæmmende virkning af ticagrelor hos raske frivillige, og det er ikke sandsynligt, at det vil have klinisk gavn hos patienter med blødninger.
platelet transfusion did not reverse the antiplatelet effect of ticagrelor in healthy volunteers and is unlikely to be of clinical benefit in patients with bleeding.

trombocytopeni (< 25x109/l eller behov for trombocyttransfusion) forekom ved median 5-6 dage hos 98 % af patienterne.
thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred at a median of 5-6 days in 98% of patients.

hvis patienten har cns-metastaser: udsæt initiering af behandlingsforløbet, og giv trombocyttransfusion, så trombocyttallet holdes på mindst 50.000/µl.
if patient has cns metastases, delay course initiation and give platelet transfusion to maintain platelet count at least 50,000/μl.

der blev givet trombocyttransfusioner i 4 % af behandlingerne.
platelet transfusions were given in 4 % of courses.